Acute generalized exanthematous pustulosis triggered by dupilumab.

Dear Editor, We present a rare but clinically significant case of acute generalized exanthematous pustulosis (AGEP) following the administration of dupilumab in a patient with refractory atopic dermatitis (AD). While dupilumab is widely regarded as a safe and effective biologic agent for moderate-to-severe AD across age groups - including adolescents, adults, and increasingly children - emerging reports underscore the need to remain vigilant for uncommon, severe cutaneous reactions. [...].